Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 21:20 IST

Ennature Bio Pharma Limited

NSE: ENNATURE · Biotechnology

Share price ₹167.65

down 6.03% · close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹375 Cr

P/E ratio

261.9

EPS FY to Mar 2026

P/B ratio

—

ROCE

—

ROE

—

Dividend yield

0.0%

as of 19 Nov 2026

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Price
Loading ENNATURE data…

At a glance · Max

Every small chart follows the range above. Point at it to read a value; click it to open it.
Revenue (sales)
₹78.5 Cr
Sep 2026 · +44.92% on a year ago
Sep 2025 – Sep 2026 · 3 quarters
Operating margin
13.2%
average 11.8% · low 11.1% · high 13.2%
Sep 2025 – Sep 2026 · 3 quarters
Net profit
₹4.89 Cr
Sep 2026
Sep 2025 – Sep 2026 · 3 quarters
EPS (yearly)
₹605.00
FY26
FY26 – FY26 · 1 year

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit ₹4.89 Cr in the quarter to Sep 2026

Announced 12 Nov 2026 · Standalone · Unaudited

Sales₹78.5 Crup 44.9% on Sep 2025
Operating profit₹10.3 Crup 71.2% on Sep 2025
Operating margin13.2%up 2.0 pts from 11.2%
Net profit₹4.89 Crno comparison with Sep 2025
Net margin6.2%up 8.6 pts from -2.4%
EPS₹2.19no comparison with Sep 2025
Sales, last 3 quarters ₹ crore
Show
Standalone
Sales, operating profit and net profit, ₹ crore: 1 year to Mar 2026.
FY26Year to Mar 2026
Sales₹246 Cr
Operating profit₹29 Cr12% of sales
Net profit₹1 Cr0.4% of sales
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales.

Years to March, 2026–2026 · key lines

Yearly profit and loss, Years to March, 2026–2026
LineMar 2026FY26
Sales₹ crore246
Operating profit₹ crore29
Operating margin% of sales12.00%
Net profit₹ crore1
EPS₹ per share605.00

Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

We do not have three full years of its sales yet, so there is nothing to compare with its sector.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

How it compares with its peers

Against companies across the whole Healthcare sector, it ranks 142 of 192 on margin.

Margin142 of 192

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

It is losing money on the capital in the business, so there is no advantage to measure.

Whether its growth pays for itself

Only 0 years of matching accounts on file — too few to judge this yet.

Peers here are the 191 companies across the whole Healthcare sector. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

19 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

Not enough filed accounts to run these checks yet.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹375 Cr
Prev close
₹167.65
52w High
₹265
52w Low
₹165
Beta
—
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Valuation

P/E ratioEPS FY to Mar 2026
261.9
Industry P/E
37.0
P/B ratio
—
EV / EBITDA
—
Enterprise value
—
PEG ratio
—
Dividend yield
0.0%

Returns

ROCE
—
ROCE 5y average
—
ROE
—
ROE 3y average
—
ROE last year
—
Return on assets
—

Sales, profit & margins

Annual revenue
₹246 Cr
Annual profit
₹1.00 Cr
EPS
₹605
Operating margin
12.0%
Net profit margin
0.4%
EBITDA margin
11.8%
Sales latest quarterSep 2026 quarter
₹78.5 Cr
Profit latest quarterSep 2026 quarter
₹4.89 Cr
OPM latest quarterSep 2026 quarter
13.2%

Growth a year

Sales growth 3y
—
Sales growth 5y
—
Sales growth TTM
—
Profit growth 3y
—
Profit growth 5y
—
Profit growth TTM
—
YoY quarterly sales growthSep 2026 vs Sep 2025
44.9%
YoY quarterly profit growth
—

Balance sheet

Book Value
₹238
Face Value
₹5.0
Borrowings
—
Total debt
₹0.00 Cr
Total cash
₹0.00 Cr
Debt / Equity
0.0
Interest coverage
1.2
Reserves / Equity
—

Cash & payout

Operating cash flow
—
Free cash flow
—
FCF yield
—
Net cash flow
—
Dividend payout
0.0%

Holdings

Promoter holding
59.6%
FII holding
2.4%
DII holding
4.6%
Public holding
33.3%

Peers

Peers
CompanyPrice ₹P/EMkt cap ₹ CrDiv yieldProfit qtr ₹ CrProfit changeSales qtr ₹ CrSales changeROCE
Sun Pharmaceutical1,884.9036.84,52,2440.86%1,995-36.16%16,199+11.88%20.60%
Divi's Laboratories11,180.5086.72,96,2830.27%1,127+63.57%3,676+35.40%21.97%
Torrent Pharmaceuticals4,689.5081.11,78,3700.82%534-9.64%4,979+50.79%19.56%
Laurus Labs Limited2,294.6092.51,23,9770.09%436+124.84%2,206+33.44%17.97%
Anthem Biosciences Limited951.0584.953,5950.21%211+22.23%594+8.00%30.45%
Advanced Enzyme Technologies Limited290.4519.73,2031.84%51.0+13.33%215+16.51%14.45%
Ennature Bio Pharma Limited167.65261.93750.00%4.8978.5+44.92%
Vivo Bio Tech Limited16.0135.50.00%1.10+26.68%17.2+31.13%7.70%
Medianof the whole group of 133, 20 Nov 202635.20.09%+30.69%+19.60%14.96%

Median: the middle value of the whole peer group of 133 companies. Price and rupee sizes are left blank there, as a middle value of those says little.

Competes with 7 listed companies

Advanced Enzyme Technologies Limited, Anthem Biosciences Limited, Divi's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Vivo Bio Tech Limited

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Standalone

This company does not publish this table.

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Standalone

This company does not publish this table.

Efficiency ratios

How fast customers pay and how well capital earns.

Standalone

This company does not publish this table.

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To Nov 2026

This company does not publish this table.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

No dividends, splits or big trades on record.

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Healthcare
Industry
Biotechnology
Symbol
ENNATURE
ISIN
INE2WCT01016

Sites · 2

  • Dehradun facilityDehradun, Uttarakhand
  • Kashipur facilityKashipur, Uttarakhand

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Revenue and margin

  • EBIT marginSep 2026 quarter8.46%

Profit quality

  • Other income shareSep 2026 quarter0.00%
  • Interest coverSep 2026 quarter265.46x

Growth

  • Revenue growth (YoY)Sep 2026 quarter44.92%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Sep 268.46%Computed from the filings
Jun 266.96%Computed from the filings
Mar 26—not filed
Dec 25—not filed
Sep 254.49%Computed from the filings

Other income share · quarterly

Source: Computed from the filings

Sep 260.00%Computed from the filings
Jun 260.00%Computed from the filings

Interest cover · quarterly

Source: Computed from the filings

Sep 26265.46xComputed from the filings
Jun 26157.25xComputed from the filings
Mar 26—not filed
Dec 25—not filed
Sep 250.64xComputed from the filings

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Ennature Bio Pharma Limited through this map.

Uses as raw material · 5

  • Centella asiatica leaves
  • Gloriosa superba seedFrom India
  • Guar beans
  • Nicotiana tabacum leaf
  • Voacanga africana seeds

Depends on the price of · 4

  • Medicinal HerbsA higher price hurts it
  • Tobacco LeafA higher price hurts it
  • fuelA higher price hurts it
  • sugarcaneA higher price hurts it

Competes with · 7 companies

Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.

8 · News & documents

News and what it reaches

Filings and news about Ennature Bio Pharma Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

No recent news or filings for this company.

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

No documents on record yet.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.